Correction to: Tumour budding-based grading as independent prognostic biomarker in HPV-positive and HPV-negative head and neck cancer (British Journal of Cancer, (2023), 128, 12, (2295-2306), 10.1038/s41416-023-02240-y)

Fabian Stögbauer, Susanne Beck, Iordanis Ourailidis, Jochen Hess, Christopher Poremba, Maren Lauterbach, Barbara Wollenberg, Anna Maria Stefanie Buchberger, Moritz Jesinghaus, Peter Schirmacher, Albrecht Stenzinger, Wilko Weichert, Melanie Boxberg, Jan Budczies

Research output: Contribution to journalComment/debate

Abstract

Springer Nature 12 18 0 2024 Springer Nature Limited 2024 Yes Unnumbered 2023 11 24 0 0 Regular NonStandardArchiveJournal Unnumbered OpenChoice OpenAccess OpenAccess OpenAccess OpenAccess OpenAccess OpenAccess false BodyRef/PDF/41416_2023_Article_2521.pdf Typeset OnlinePDF 2024 2 5 2024 2 5 Regular Erratum Biomedicine Biomedicine, general Cancer Research Epidemiology Molecular Medicine Oncology Drug Resistance Biomedical and Life Sciences true Correction to: British Journal of Cancerhttps://doi.org/10.1038/s41416-023-02240-y, published online 12 April 2023 The original version of this article contained a mistake. In the Methods section, under the heading TCGA cohort, the sentence originally read as follows: “HPV status was determined based on the number of RNA sequencing reads aligning to the viral genes E6 and E7 as previously described [27, 28].” The corrected version is: “HPV status was determined by investigating the tumour DNA with a PCR based assay interrogating 16 HPV types (16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68, 73, and 90) as previously described [27]. Tumours were classified as HPV+ when the test result was positive, as HPV- when the test result was negative and excluded from the analysis when the test result was indeterminate.” The complete, corrected section can be found below. The correction does not have any effect on the results or conclusions of the paper. TCGA cohort The TCGA-HNSC cohort included a total of 528 patients who were treated for HNSCC [27, 28]. Digitised H&E-stained diagnostic slides of 471 cases were available from the GDC Data Portal (https://portal.gdc.cancer.gov). A total of 331 tumours consisting of conventional, basaloid, verrucous, and papillary HNSCC were included into the study after exclusion of 140 cases. Cases were excluded due to the following reasons: small biopsy specimen precluding the analysis of 10 HPF, a different tumour entity, sarcomatoid histomorphology, not enough tumour on slide, inferior scan quality, exposed carcinoma without relation to surrounding stroma precluding the analysis of TB, duplicates and a history of neoadjuvant treatment. HPV status was determined by investigating the tumour DNA with a PCR based assay interrogating 16 HPV types (16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68, 73, and 90) as previously described [27]. Tumours were classified as HPV+ when the test result was positive, as HPV- when the test result was negative and excluded from the analysis when the test result was indeterminate. The clinicopathological characteristics of the study cohort are shown in Supplementary Table S1. The original article has been corrected.

Original languageEnglish
Pages (from-to)511
Number of pages1
JournalBritish Journal of Cancer
Volume130
Issue number3
DOIs
StatePublished - 24 Feb 2024
Externally publishedYes

Fingerprint

Dive into the research topics of 'Correction to: Tumour budding-based grading as independent prognostic biomarker in HPV-positive and HPV-negative head and neck cancer (British Journal of Cancer, (2023), 128, 12, (2295-2306), 10.1038/s41416-023-02240-y)'. Together they form a unique fingerprint.

Cite this